Targeting inflammation in the treatment of type 2 diabetes (Q38134116)

29 August 2017

Targeting inflammation in the treatment of type 2 diabetes (English)

1 reference

29 August 2017

0 references

1 reference

M Y Donath

1

1 reference

PubMed ID

24003937

29 August 2017

language of work or name

1 reference

1 September 2013

1 reference

Diabetes, Obesity and Metabolism

29 August 2017

1 reference

29 August 2017

15 Suppl 3

1 reference

29 August 2017

193-196

1 reference

Is type II diabetes mellitus a disease of the innate immune system?

29 August 2017

1 reference

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

21 January 2018

1 reference

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

21 January 2018

1 reference

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

The role of inflammatory cytokines in diabetic nephropathy.

21 January 2018

1 reference

Increased number of islet-associated macrophages in type 2 diabetes.

21 January 2018

1 reference

Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

21 January 2018

1 reference

Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet.

21 January 2018

1 reference

Thioredoxin-interacting protein links oxidative stress to inflammasome activation

21 January 2018

1 reference

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

21 January 2018

1 reference

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling

21 January 2018

1 reference

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

21 January 2018

1 reference

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

21 January 2018

1 reference

IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.

21 January 2018

1 reference

Muscle-derived interleukin-6: mechanisms for activation and possible biological roles

21 January 2018

1 reference

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

21 January 2018

1 reference

Identification of autoantibody-negative autoimmune type 2 diabetic patients

21 January 2018

1 reference

Effects of etanercept in patients with the metabolic syndrome

21 January 2018

1 reference

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome

21 January 2018

1 reference

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

21 January 2018

1 reference

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome

21 January 2018

1 reference

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

21 January 2018

1 reference

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

21 January 2018

1 reference

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

21 January 2018

1 reference

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

21 January 2018

1 reference

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

21 January 2018

1 reference

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

21 January 2018

1 reference

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

21 January 2018

1 reference

Salsalate improves glycemia and inflammatory parameters in obese young adults

21 January 2018

1 reference

Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12172

1 reference

29 August 2017

1 reference

PubMed ID

24003937